# Avance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership

- Link: https://www.thailand-business-news.com/pr-news/avance-clinical-receives-frost-sullivans-2026-global-company-of-the-year-recognition-for-excellence-in-biotech-cro-leadership
- Published: 2026-05-12T19:00:00+07:00
- Author: PR Newswire

_The company is recognized for its innovation, scientific expertise, and customer-
centric clinical development model in the global biotechnology CRO market_

SAN ANTONIO, May 12, 2026 /PRNewswire/ — [Frost & Sullivan](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684174-1&h=3849278112&u=https%3A%2F%2Fwww.frost.com%2F&a=Frost+%26+Sullivan)
is pleased to announce that [Avance Clinical](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684174-1&h=2169789188&u=http%3A%2F%2Fwww.avancecro.com%2F&a=Avance+Clinical)
has been awarded the 2026 Global Company of the Year Recognition in the biotechnology
contract research organization (CRO) industry for its outstanding achievements in
innovation, strategy execution, and customer impact. This recognition highlights
Avance Clinical’s consistent leadership in advancing biotech clinical development,
strengthening its global market position and delivering tailored, high-quality solutions
in an increasingly complex and competitive CRO landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across
two core dimensions: strategy effectiveness and strategy execution. Avance Clinical
excelled in both, demonstrating its ability to align closely with biotech sponsor
needs while executing with speed, precision, and scalability. "Avance Clinical stands
out for its ability to align deeply with the unique pressures of biotech development,
combining scientific rigor, operational agility, and continuity across clinical 
phases to deliver measurable progress for sponsors," said Unmesh Lal, Vice President
at Frost & Sullivan.

Guided by a long-term growth strategy centered on biotech specialization, global
expansion, and operational integration, Avance Clinical leads the rapidly evolving
clinical research environment. The company’s strategic focus on early-phase development,
combined with its GlobalReady model, enables seamless progression from Phase I through
later-stage trials across regions, including the United States, Asia-Pacific, and
Europe.

Innovation is central to Avance Clinical’s approach. Its comprehensive suite of 
clinical development services meets the evolving demands of biotechnology companies
by offering speed to clinics, regulatory flexibility, and data-driven insights. 
By leveraging Australia’s rapid study start-up timelines and cost efficiencies, 
alongside advanced analytics and AI-enabled data systems, the company enhances trial
execution while improving visibility into program performance.

"We are honored to receive Frost & Sullivan’s 2026 Global Biotechnology CRO of the
Year Recognition, reflecting the strength of our team and our commitment to advancing
biotech innovation. This recognition highlights our ability to help our biotech 
clients accelerate timelines with our focus and strength in Australia, coupled with
our global operations to power patient enrollment for later phase studies," said
Mark Harvill, Chief Executive Officer at Avance Clinical.

Harvill continued, "We continue to drive global growth while adapting to an evolving
clinical landscape through digital transformation including AI adoption across our
global operations, data-driven decision-making, and further strategic expansion.
We remain focused on partnering with biotech innovators to accelerate development
in Australia and globally as we bring new therapies to patients."

Avance Clinical’s unwavering commitment to customer experience further strengthens
its position in the market. By embedding senior leadership into project teams, maintaining
continuity across studies, and tailoring delivery models to individual sponsor needs,
the company operates as a true extension of its clients. Its emphasis on transparency,
direct communication, and milestone alignment enables biotech sponsors to navigate
funding pressures, regulatory complexity, and accelerated development timelines 
with greater confidence.

The company’s investment in therapeutic expertise and regional expansion reinforces
its competitive differentiation. Focused capability growth in oncology, central 
nervous system, and cardiometabolic research, along with the establishment of Centers
of Excellence, enhances its ability to support complex, high-value programs. At 
the same time, its expansion across Asia Pacific and strengthened regulatory infrastructure
position Avance Clinical as a key partner for multi-regional clinical trials.

Frost & Sullivan commends Avance Clinical for setting a high standard in competitive
strategy, execution, and market responsiveness. The company’s biotech-focused model,
commitment to innovation, and ability to deliver continuity across the clinical 
development life cycle are shaping the future of the CRO industry and driving tangible
outcomes for sponsors worldwide.

Each year, Frost & Sullivan presents the Company of the Year Recognition to a company
that demonstrates outstanding strategy development and implementation, resulting
in measurable improvements in market share, customer satisfaction, and competitive
positioning. The recognition honors forward-thinking organizations that are redefining
their industries through innovation and growth excellence.

**Frost & Sullivan Best Practices RecognitionFrost & Sullivan’s Best Practices Recognitions
honor companies across regional and global markets that exhibit exceptional achievement
and consistent excellence in areas such as leadership, technological innovation,
customer experience, and strategic product development. Each recognition is the 
result of a rigorous analytical process in which Frost & Sullivan industry experts
benchmark performance through comprehensive interviews, deep-dive analysis, and 
extensive secondary research. The goal is to identify true best-in-class organizations
that are driving transformative growth and setting new industry standards.
[Contact us: Start the discussion](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684174-1&h=1291047530&u=https%3A%2F%2Fww2.frost.com%2Fcontact-us%2F&a=Contact+us%3A+Start+the+discussion).

Contact:

Tarini Singh
E: [Tarini.Singh@frost.com](https://www.thailand-business-news.com/pr-news/Tarini.Singh@frost.com)

**About Avance ClinicalAvance Clinical is a leading Contract Research Organization(
CRO) offering biotech companies faster, more flexible, and higher-quality clinical
trial services. As the largest premium full-service CRO headquartered in [Australia](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684174-1&h=4023178409&u=https%3A%2F%2Fwww.avancecro.com%2Fthe-australian-advantage%2F&a=Australia),
Avance Clinical delivers globally accepted data across Australia, New Zealand, [Asia](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684174-1&h=2552334661&u=https%3A%2F%2Fwww.avancecro.com%2Fthe-asia-advantage%2F&a=Asia),
[North America](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684174-1&h=3406920108&u=https%3A%2F%2Fwww.avancecro.com%2Fthe-north-american-advantage%2F&a=North+America),
the UK and Europe for international biotechs. With 30 years of experience and expertise
spanning over more than 250 indications, the company provides comprehensive clinical
research services from early to late-phase trials.
[www.avancecro.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684174-1&h=3711669925&u=https%3A%2F%2Fwww.avancecro.com%2F&a=www.avancecro.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Avance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership ](http://www.prnasia.com/story/archive/4954846_AE54846_0?rand=184833)